Date: 2013-11-12
Type of information: Collaboration agreement
Compound:
Company: Nicox (France) Sjögren’s Syndrome Foundation
Therapeutic area: Ophtalmological diseases - Rare diseases
Type agreement:
Action mechanism:
Disease: Sjögren’s Syndrome
Details: * On November 12, 2013, Nicox has announced that it has formed a partnership with the Sjögren’s Syndrome Foundation to raise awareness of the disease among eye care professionals. The company has also announced that Sjö™, an advanced diagnostic panel for the early detection of Sjögren’s Syndrome, has been launched in the US. Sjö™ is a proprietary laboratory test developed by Immco Diagnostics Inc. which combines traditional markers with three novel, proprietary biomarkers, allowing earlier detection of the disease. It will be promoted to US eye care professionals by Nicox’s US sales force under an exclusive North American agreement signed with Immco in June 2013. Sjö™ is the second product launched by Nicox in the US following the launch of AdenoPlus®, a rapid point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis, in October 2012.
Financial terms:
Latest news:
